Egalet Corporation (NASDAQ:EGLT) Ratings Summary on May 16, 2018

May 16, 2018 - By Sheila Anderson

Egalet Corporation (NASDAQ:EGLT) Corporate Logo
During 2017 Q4 the big money sentiment decreased to 0.47. That’s change of 0.11, from 2017Q3’s 0.58. 13 investors sold all, 17 reduced holdings as Egalet Corporation ratio turned negative. 8 grew positions while 6 funds acquired positions. Funds hold 13.62 million shares thus 32.80% less from 2017Q3’s 20.27 million shares.
Two Sigma Secs Ltd Liability Company reported 57,835 shs or 0% of all its holdings. Tiverton Asset Mgmt Ltd Co reported 0% of its capital in Egalet Corporation (NASDAQ:EGLT). Northern Tru Corp, Illinois-based fund reported 97,109 shs. J Goldman Com Limited Partnership holds 100,000 shs. Goldman Sachs Group accumulated 68,731 shs. Janney Montgomery Scott Ltd Limited Liability Company reported 22,159 shs stake. 28,500 are held by California Public Employees Retirement. Fmr Ltd holds 767,013 shs. Blackrock Inc holds 0% of its capital in Egalet Corporation (NASDAQ:EGLT) for 430,103 shs. Barclays Public Limited Company owns 65 shs. Atlantic Trust Gru has invested 0% of its capital in Egalet Corporation (NASDAQ:EGLT). Advisory Svcs Network Ltd Llc reported 1,835 shs stake. Morgan Stanley reported 0% in Egalet Corporation (NASDAQ:EGLT). D E Shaw And holds 0% or 299,312 shs. Geode Cap Mgmt Ltd Limited Liability Company holds 67,633 shs.

Egalet Corporation (NASDAQ:EGLT) Ratings Coverage

In total 2 analysts cover Egalet (NASDAQ:EGLT). “Buy” rating has 0, “Sell” are 0, while 2 are “Hold”. (NASDAQ:EGLT) has 0 bullish analysts. 3 are the (NASDAQ:EGLT)’s ratings reports on May 16, 2018 according to StockzIntelligence Inc. On Tuesday, May 8 the stock of Egalet Corporation (NASDAQ:EGLT) has “Hold” rating given by Cantor Fitzgerald. On Monday, March 12 the firm earned “Buy” rating by Cantor Fitzgerald. On Wednesday, January 3 the firm has “Hold” rating given by Stifel Nicolaus. Listed here are Egalet Corporation (NASDAQ:EGLT) PTs and latest ratings.

08/05/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $1.5000 Downgrade
12/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $3.5 Maintain
03/01/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Hold Downgrade

The stock decreased 11.50% or $0.06 during the last trading session, reaching $0.5.Egalet Corporation has 2.09M shares volume, 142.29% up from normal. EGLT is downtrending and has moved 87.31% since May 16, 2017. The stock underperformed the S&P 500 by 98.86%.

Egalet Corporation, a specialty pharmaceutical company, develops, makes, and commercializes treatments for patients with pain and other conditions.The firm is valued at $26.43 million. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic moderate to severe pain where an opioid is appropriate; and ARYMO ER, an extended-release morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.Currently it has negative earnings. The firm is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER.

There’s a substantial Egalet Corporation (NASDAQ:EGLT) news published by Seekingalpha.com. It’s an item titled: “Egalet’s (EGLT) CEO Bob Radie on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018.

Egalet Corporation (NASDAQ:EGLT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.